FLT3 and renal cell adenocarcinoma: For example, Sorafenib and Sunitinib are two drugs that have been approved for the therapeutic management of advanced‐stage renal cell cancer, which can depress the development of renal cell cancer by inhibiting VEGFR, PDGFR, and FLT3 expression levels [3, 52].